TDO2

Across TCGA pan-cancer cohorts, TDO2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TDO2 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher TDO2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TDO2 expression acts as an unfavorable survival marker.

SCLC, LUSC, and UCEC are the cancer types where TDO2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	II,III,IV	0.137	0.602	.008	15	view →
LUSC	OS	Median	II,III,IV	0.196	0.742	.010	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SKCM	DFS	Median	III,IV	0.046	0.648	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TDO2–SCLC (DFS)

Open the SCLC breakdown →